Urine RNA Test Guided Bladder Cancer Treatment

Researchers developed a noninvasive test that predicts patient response to immunotherapy for bladder cancer.

Updated on Oct. 13, 2026 in Cancer

Urine RNA Test Guided Bladder Cancer Treatment

Live Poll

Would you trust a non-invasive urine test over a surgical procedure for cancer monitoring?

Scientists have created a novel urine cell-free RNA test to identify which bladder cancer patients will benefit from Bacillus Calmette-Guérin (BCG) immunotherapy. This noninvasive method offers a promising alternative to traditional monitoring techniques like cystoscopy.

Why it matters

The test aims to improve treatment outcomes by predicting how effectively a patient will respond to BCG therapy while reducing the need for invasive diagnostic procedures. By identifying specific immune signals, clinicians can better tailor care for individuals with bladder cancer.

In a study of 515 individuals, the test achieved a 96% sensitivity rate in a 93-patient cohort and 99% in an 85-patient cohort. These results outperform traditional DNA-based testing, which showed 85% sensitivity, and cytology, which yielded 34%.

The players

Stanford University

This academic institution served as the base for the research team that developed the new diagnostic method.

Palo Alto VA

This medical facility functioned as a site for participant enrollment during the study.

The details

The diagnostic method analyzes fragmented RNA from urine samples to profile gene expression and distinguish between cancer grades. Researchers trained a model to correlate these specific T-cell immune signals and tumor proliferation markers with patient responses to BCG treatment.

October 2026: Findings were published in Nature Medicine.

Health Landscape

This development follows the broader trajectory of noninvasive liquid biopsy diagnostics, which seek to move away from invasive procedures like cystoscopy. By focusing on gene expression profiling, it shifts clinical oncology toward more precise, biomarker-driven treatment monitoring.

This diagnostic test could eventually provide patients with a less invasive way to monitor bladder cancer and determine the effectiveness of immunotherapy. It aims to reduce the physical discomfort associated with repeat cystoscopies while helping physicians avoid ineffective treatments.

The takeaway

This study demonstrates that analyzing urine for specific genetic markers can effectively predict treatment responses. Patients should consult with their oncologists to see if emerging liquid biopsy technologies may impact their future treatment planning.